We focus on cases where the most advanced, relevant treatment option is concentrated in the United States and difficult to reach locally.
Including inherited conditions such as Usher syndrome, where specialized trials and therapies are concentrated in a small number of U.S. centers.
Conditions where the majority of active, relevant trials are registered and run within the United States.
Cases where standard treatment options at home are limited, exhausted, or unavailable, and further options require specialist review.
Emerging therapies, including gene and cell-based treatments, that are approved or trialed primarily within U.S. institutions.
Patients seeking an independent, specialized U.S. clinical opinion before committing to a treatment path at home.
Complex presentations without a clear diagnosis, where access to specialized U.S. diagnostic programs may provide answers.
Every case is reviewed individually rather than matched against a fixed checklist. If your condition is rare, complex, progressive, or you've been told the most advanced option may be in the United States, it's worth starting a case review — there is no obligation to proceed afterward.